Addition of plerixafor for CD 34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation

Background I n allogeneic hematopoietic stem cell ( HSC ) transplantation, collection of a sufficient number of HSCs at a fixed time point is crucial. For HSC mobilization into the peripheral blood, the standard regimen, that is, granulocyte–colony‐stimulating factor ( G ‐ CSF ), may be inadequate. Use of plerixafor as adjuvant to G ‐ CSF is so far off‐label in healthy donors. Study Design and Methods We present six cases in which the “just‐in‐time” addition of plerixafor ensured proper CD 34+ collection from healthy donors with insufficient G ‐ CSF mobilization. In four of these cases a high number of CD 34+ cells was needed due to subsequent CD 34+ selection or haploidentical transplantation. Results From all six donors a sufficient number of CD 34+ cells was obtained by using plerixafor as an adjuvant to G ‐ CSF . This treatment regimen resulted in only mild side effects for the donor. Conclusion We have presented six cases with different causes leading to insufficient G ‐ CSF mobilization in allogeneic donors and in which the administration of plerixafor just‐in‐time ensured a proper graft for transplantation.